Kohl's Corporation vs Mesoblast Limited — how do they compare? Kohl's Corporation trades at $17.41 (market cap $1.99B), while Mesoblast Limited trades at $16.08 (market cap $2.17B). The key difference: Kohl's Corporation and Mesoblast Limited are close in size by market cap, and Kohl's Corporation pays a 2.85% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KSS | MESO | |
|---|---|---|
Market Cap | $1.99B | $2.17B |
Sector | Consumer Cyclical | Technology |
52-Week High | $24.71 | $20.96 |
52-Week Low | $10.42 | $12.88 |
Enterprise Value | $8.10B | $2.17B |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Trailing returns across standard periods
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →